---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135264"
form_type: "8-K"
ticker: null
cik: "0001785173"
company_name: "89bio, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:40:17.508584+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 89bio reports Q1 net loss of $51.7M; initiates Phase 3 MASH trial

## Summary
- Net loss $51.7M vs $28.8M YoY; R&D expenses $47.4M (up from $22.3M) on trial ramp-up.
- Cash, equivalents & marketable securities $562.3M as of March 31, 2024.
- Initiated Phase 3 ENLIGHTEN-Fibrosis trial in MASH F2-F3; ENLIGHTEN-Cirrhosis expected Q2 2024.
- EMA granted PRIME status for pegozafermin in MASH; 48-week extension data at EASL June 8.
- ENTRUST Phase 3 in severe hypertriglyceridemia enrollment ongoing; topline data expected 2025.

## SEC filing metadata
- accession: 0001193125-24-135264
- form_type: 8-K
- cik: 0001785173
- company_name: 89bio, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/0001193125-24-135264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/d793786d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135264
- JSON: https://secwatch.observer/filing/0001193125-24-135264.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135264.txt

## Key facts
- Earnings Releases
  89bio, Inc. reported the first quarter ended March 31, 2024 results: net income $51.7 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: $51.7 million
  - Result: reported results
  source text: 89bio reported a net loss of $51.7 million for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/0001193125-24-135264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.